Cryo-Cell International Completes Real Estate Acquisition For Its Cell Therapy Institute



Cryo-Cell International (symbol: CCEL) acquires a property for its Cell Therapy Institute in the Raleigh-Durham area.

MIAMI, 20 Aug 2021 (GLOBE NEWS) – The Institute’s First Clinic for Cell Therapy is conveniently located in Durham, North Carolina, close to Raleigh Durham International Airport (International Airport). An institution with an area of ​​8 326 sq. Ft is conveniently located with several hotels to choose from for families expected to travel from around the world to the Institute for cell therapy.

Cryo-Cell Chairman and Co-CEO David Portnoy said: “We are very pleased with this acquisition and look forward to providing access to FDA-approved clinical trials programs for patients requiring cord blood cell therapy as soon as possible. The number of patients awaiting treatment is large and growing. ”

The architectural design of the reconstruction of the clinic, which is scheduled to open in early 2022, has already begun. The clinic is expected to be equipped with the most advanced technology, the safest and most effective, yet child-friendly, layout possible and meet all guidelines and the latest COVID protection guidelines.

The Institute for Cryocells for Cell Therapy will offer FDA-regulated cord blood products to treat conditions such as autism spectrum disorders, cerebral palsy and hypoxic brain damage.

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc., founded in 1989, is the world’s first privately owned cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their child’s umbilical cord blood and cord tissue stem cells. In addition to a private bank, Cryo-Cell International has a public banking program in partnership with Duke University. State Bank Cryo-Cell has provided cord blood for over 600 transplants and operates cord blood donation sites throughout the United States at renowned hospitals such as Cedars Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell is FDA registered, cGMP- / cGTP compliant and licensed in all states requiring a license. In addition to being accredited by the AABB as a cord blood institution, Cryo-Cell was also the first U.S. (private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized independent accrediting organization. … Cryo-Cell holds exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology.

Cryo-Cell’s mission was to provide clients with the most advanced cryopreservation services for umbilical cord blood and umbilical cord tissue, to raise awareness of the possibility for future parents to store or donate their baby’s umbilical cord blood, and to support the development of regenerative medicine. In February 2021, Cryo-Cell entered into a licensing agreement with Duke University that transformed Cryo-Cell into a stand-alone, vertically integrated cell therapy company that could treat patients.

For more information please visit

Forward-looking statement

Statements in this document the terms “believes,” “intends,” “plans,” “expects,” “expects,” and similar expressions used in this document are intended to reflect the “forward-looking statements” of the Company. The information contained in this document is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those expected in such forward-looking statements or paragraphs, many of which are beyond the control of the Company. These uncertainties and other factors include the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the company’s global expansion and product diversification initiatives, and the Company’s actual future stake in future treatments arising from its joint research partnerships. , the success associated with its intellectual property portfolio, the future competitive position of the Company in stem cell innovation, the future success of its core business and the competitive influence of state-owned cord blood banks on the Company’s business, the success of the Company’s initiative to expand its core business to business units to include biopharmaceuticals and operating clinics, the uncertainty of the profitability of its biopharmaceutical production and operating clinics, the Company’s ability to minimize the future costs of the Company associated with initiatives and collaborations in the field of R&D, as well as the success of such initiatives and collaborations, the success and applicability of Com pany cord blood and cord tissue licensing agreements , as well as the corresponding intellectual property and their ability to provide the Company with fees, as well as those risks and uncertainties that are contained in the risk factors described in the documents that the Company from time to time The Exchange holds with the Securities the Exchange Commission, including the most recent Form 10-K Annual Report, Quarterly Form 10-Q Reports, and any current Form 8-K reports filed by the Company. The Company disclaims any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

For more information, please contact:
Corporate Communications / Investor Relations
Diane Glantz, Rph, PharmD.
Phone: +1 (813) 749-2195
Email address:


Source link